Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics has filed an S-3/A shelf registration statement for the resale of up to 41,630,514 shares of common stock by selling stockholders. The shares include 20,790,120 outstanding shares, 6,963,556 shares issuable from pre-funded warrants, and 13,876,838 shares from common warrants issued in a private placement on May 27, 2025.
The company is advancing genetic medicine treatments for cardiovascular diseases. Key highlights:
- LX2006 for Friedreich ataxia cardiomyopathy shows promising Phase 1/2 results with improvements in cardiac biomarkers and frataxin protein expression
- LX2020 for PKP2 arrhythmogenic cardiomyopathy is in Phase 1/2 trials
- FDA alignment achieved on accelerated approval pathway with co-primary endpoints
As an emerging growth company and smaller reporting company, Lexeo's stock trades on Nasdaq under LXEO with last quoted price of $4.19 on June 25, 2025. The company will not receive proceeds from the stock sales but will receive proceeds from any warrant exercises.